Related Experiment Video
Updated: Jul 17, 2025

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Prognostic Implications and Efficacy of Catheter Ablation by Atrial Fibrillation Type
Hiroshi Miyama1, Seiji Takatsuki1, Nobuhiro Ikemura1,2
1Department of Cardiology Keio University School of Medicine Tokyo Japan.
Insights
Persistent atrial fibrillation (PersAF) is linked to worse outcomes than paroxysmal atrial fibrillation (PAF). Catheter ablation (CA) may reduce adverse events for both AF types, but careful consideration of AF type is crucial.
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Research
Background:
- Catheter ablation (CA) is standard for paroxysmal atrial fibrillation (PAF) but selectively used for persistent atrial fibrillation (PersAF).
- Differences in prognosis and the impact of CA between PAF and PersAF are not fully understood.
Purpose of the Study:
- To compare clinical outcomes and quality of life between patients with PAF and PersAF.
- To evaluate the effectiveness of CA in both PAF and PersAF patients.
Main Methods:
- Analysis of a multicenter atrial fibrillation (AF) cohort study with 2788 patients categorized as PAF (≤7 days) or PersAF (>7 days).
- Comparison of a composite outcome (death, heart failure hospitalization, stroke, bleeding) and Atrial Fibrillation Effect on Quality-of-life (AFEQoL) scores over 2 years.
- Propensity score matching to compare CA versus medication in both AF types.
Main Results:
- PersAF patients had higher composite event rates (12.8% vs. 7.2%) and poorer AFEQoL improvement than PAF patients.
- PersAF independently predicted adverse outcomes (aHR=1.35) and was linked to worse AFEQoL.
- CA significantly reduced adverse events in PAF (OR=0.31) and showed a similar trend in PersAF.
Conclusions:
- Persistent atrial fibrillation is a significant risk factor for adverse clinical outcomes and diminished quality of life.
- Catheter ablation is associated with reduced adverse events, particularly in PAF, suggesting its potential benefit in PersAF requires careful patient selection.
Abstract:
Background Catheter ablation (CA) for atrial fibrillation (AF) is preferred for paroxysmal AF (PAF) but selectively performed in patients with persistent AF (PersAF). This study aimed to investigate the prognostic differences and consequences of CA based on the AF type. Methods and Results Data from a multicenter AF cohort study were analyzed, categorizing patients as PAF or PersAF according to AF duration (≤7 or >7 days, respectively). A composite of all-cause death, heart failure hospitalization, stroke, and bleeding events during 2-year follow-up and changes in the Atrial Fibrillation Effect on Quality-of-life score were compared. Additionally, propensity score matching was performed to compare clinical outcomes of patients with and without CA in both AF types. Among 2788 patients, 51.6% and 48.4% had PAF and PersAF, respectively. Patients with PersAF had a higher incidence of the composite outcome (12.8% versus 7.2%; P<0.001) and smaller improvements in Atrial Fibrillation Effect on Quality-of-life scores than those with PAF. After adjusting for baseline characteristics, PersAF was an independent predictor of adverse outcomes (adjusted hazard ratio, 1.35 [95% CI, 1.30-1.78], P=0.031) and was associated with poor improvements in Atrial Fibrillation Effect on Quality-of-life scores. Propensity score matching analysis showed that the CA group had significantly fewer adverse events than the medication group among patients with PAF (odds ratio, 0.31 [95% CI, 0.18-0.68]; P=0.002). Patients with PersAF showed a similar but nonsignificant trend. Conclusions PersAF is a risk factor for worse clinical outcomes, including patients' health status. CA is associated with fewer adverse events, although careful consideration is required based on the AF type.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy V: Interprofessional Care

